References
- Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther. 2012;34:400–19
- National Cancer Institute. Biological therapy; 2013. Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/biological. Accessed April 14, 2015
- Chu R, Torstensson D, Pugatch M. Patient safety & comfort: the challenges of switching medicines; 2010. Availble from: http://www.stockholm-network.org/downloads/publications/Patient_Safety_and_Comfort___The_Challenges_of_Switching.pdf. Accessed April 14, 2015
- Hoffman JM, Thomas EL, Dombrowski SR. A health-system pharmacist’s guide to biosimilars: regulatory, scientific & practical consideration; 2013. Available from: www.biosimcentral.org
- Congressional Budget Office. S. 1695, Biologics Price Competition and Innovation Act of 2007. Washington, DC: Congressional Budget Office; 2008
- Gravel P, Naik A, Le Cotonnec JY. Biosimilar rhG-CSFs: how similar are they? Target Oncol. 2012;7:29–34
- Chu R, Pugatch M. Biogenerics or biosimilars? Discussing the present, considering the future; 2009. Available from: http://www.stockholm-network.org/downloads/publications/Biosimilars_FINAL.pdf. Accessed April 14, 2015
- DeMartino JK. Biosimilars: approval and acceptance? J Natl Compr Canc Netw. 2011;9:S6–9
- Chhina M. Overview of biological products. U.S. Food and Drug Administration; 2013
- Kanter J, Feldman R. Understanding and incentivizing biosimilars. 2012. Available from: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2222870##. Accessed April 14, 2015
- Kresse GB. Biosimilars – science, status, and strategic perspective. Eur J Pharm Biopharm. 2009;72:479–86
- Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res. 2007;30:267–72
- American Pharmacist Association. The biosimilar pathway: where will it lead us? Pharmacy Today. 2011;17:67–76
- Robinson DK, Sethuraman N. How innovative technology is moving biologics into the 21st century. Clin Pharmacol Ther. 2010;87:261–3
- Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310–12
- Zelenetz AD, Ahmed I, Braud EL, et al. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011;9:S1–22
- Hulse WL, Gray J, Forbes RT. Evaluating the inter and intra batch variability of protein aggregation behaviour using Taylor dispersion analysis and dynamic light scattering. Int J Pharm. 2013;453:351–7
- Zuñiga L, Calvo B. Biosimilars approval process. Regul Toxicol Pharmacol. 2010;56:374–7